cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2013-4-67-74cardiovascular-216Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯCLINICAL STUDIESЦЕНТРАЛИЗОВАННОЕ ИССЛЕДОВАНИЕ ПО ОЦЕНКЕ ЭФФЕКТИВНОСТИ ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ В РОССИИ (CEPHEUS)CENTRALISED SURVEY ON THE UNDERTREATMENT OF THE HYPERCHOLESTEROLEMIA IN RUSSIA (CEPHEUS)БойцовС. А.BoytsovS. A.

д. м.н., профессор, директор

Тел.: +7 (495) 623-86-36; факс: +7 (495) 621-01-22 

tel.: +7 (495) 623-86-36; факс: +7 (495) 621-01-22

prof.boytsov@gmail.comХомицкаяЮ. В.KhomitskayaYu. V.

руководитель группы медицинских советников, кардиология

Государственный научно-исследовательский центр профилактической медициныРоссияState Research Centre for Preventive Medicine, MoscowRussian FederationМедицинский отдел, компания АстраЗенека, МоскваРоссияMedical Division, AstraZeneca, MoscowRussian Federation2013200820131246774Copyright © Бойцов С.А., Хомицкая Ю.В., 20132013Бойцов С.А., Хомицкая Ю.В.Boytsov S.A., Khomitskaya Y.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/216Цель

Цель. Оценить долю больных, получающих гиполипидемическую медикаментозную терапию, у которых достигнуты целевые значения холестерина липопротеинов низкой плотности (ХС ЛНП), определенные согласно рекомендациям Всероссийского научного общества кардиологов (ВНОК) /Четвертой объединенной европейской рабочей группы (4JETF).

Материал и методы

Материал и методы. Исследование CEPHEUS – многоцентровое, одномоментное, наблюдательное исследование с участием пациентов из России, получающих гиполипидемическую терапию в течение не менее 3 мес. (без изменения дозы ≥6 нед.). Исследование началось 22.10.2010г. и завершилось 22.03.2011г. Сбор данных осуществлялся во время однократного визита.

Результаты

Результаты. В исследование были включены 1 тыс. пациентов. В целом целевые уровни ХС ЛНП в соответствии с рекомендациями ВНОК и 4JETF в рутинной клинической практике были достигнуты у 34,5% и 48,2% пациентов, соответственно. Пациенты, получавшие липидснижающую терапию в рамках вторичной профилактики сердечно-сосудистых осложнений (ССО), по сравнению с лицами, лечившимися с целью первичной профилактики, чаще достигали целевых уровней ХС ЛНП в соответствии с рекомендациям ВНОК – 27,0% и 38,2% (p=0,001; отношение рисков (ОР) 1,67; 95% доверительный интервал (ДИ) [1,22–2,28]) и 4JETF – 35,4% и 54,5% (p<0,001; ОР 2,19; 95% ДИ [1,63–2,95]).

Заключение

Заключение. Целевых значений ХС ЛНП в России достигают <50% пациентов, получающих гиполипидемическую терапию. У пациентов, при лечении в рамках первичной профилактики, частота достижения целевых значений ниже.

Aim

Aim. To assess the percentage of the patients who receive lipid-lowering drug therapy and achieve target levels of low-density lipoprotein cholesterol (LDL–CH), in accordance with the recommendations by the Russian Cardiology Society (RCS) and the 4th Joint European Task Force (4JETF).

Material and methods

Material and methods. The CEPHEUS study is a multi-centre, cross-sectional observational study with the participation of Russian patients. The study participants received lipid-lowering therapy for at least 3 months (no dose modification for ≥6 weeks). The start-date and end-date of the study were Oct 22nd 2010 and Mar 22nd 2011, respectively. The cross-sectional data were collected during a single visit to the clinic.

Results

Results. The study included 1000 Russian patients. Overall, target LDL–CH levels were achieved in 34,5% (RCS criteria) and 48,2% (4JEFT criteria) of the patients who received lipid-lowering therapy in the routine clinical practice. The patients who were treated for secondary prevention of cardiovascular events (CVE) achieved target levels of LDL–CH more often than the patients treated for primary prevention: 38,2% vs. 27,0%, respectively, by the RCS criteria (odds ratio (OR) 1,67; 95% confidence interval (CI) 1,22–2,28; p=0,001) and 54,5% vs. 35,4%, respectively, by the 4JEFT criteria (OR 2,19; 95% CI 1,63–2,95; p<0,001).

Conclusion

Conclusion. Target levels of LDL–CH are achieved by <50% of the Russian patients who receive lipid-lowering treatment. This percentage is even lower in patients receiving lipid-lowering treatment for primary CVE prevention.

холестеринлипопротеины низкой плотностисердечно-сосудистые заболеванияпрофилактика и контрольдислипидемиянаблюдательные исследованияcholesterollow-density lipoproteinscardiovascular diseaseprevention and controldyslipidemiaobservational studiesReferencesBritish Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics 2008 Edition [updated 2008 January 8]. Available from: http://www.bhf.org.uk/publications/view-publication. aspx?ps=1001443. Accessed October 24, 2012.British Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics 2008 Edition [updated 2008 January 8]. Available from: http://www.bhf.org.uk/publications/view-publication. aspx?ps=1001443. Accessed October 24, 2012.Statistical Yearbook of Russia. MoscowRosstat 2009; 795 p. Russian (Российский статистический ежегодник. 2009. Стат. сб. Росстат. Москва 2009; 795 с).Statistical Yearbook of Russia. MoscowRosstat 2009; 795 p. Russian (Российский статистический ежегодник. 2009. Стат. сб. Росстат. Москва 2009; 795 с).Bokeriya LA, Gudkova RG. Disease and congenital anomalies of circulatory system. Moscow: AN Bakulev RAMS; 2009, 162 p. Russian (Бокерия Л. А., Гудкова Р. Г. Сердечно-сосудистая хирургия-2008. Болезни и врожденные аномалии системы кровообращения. М.: НЦССХ им. А. Н. Бакулева РАМН 2009; 162 с).Bokeriya LA, Gudkova RG. Disease and congenital anomalies of circulatory system. Moscow: AN Bakulev RAMS; 2009, 162 p. Russian (Бокерия Л. А., Гудкова Р. Г. Сердечно-сосудистая хирургия-2008. Болезни и врожденные аномалии системы кровообращения. М.: НЦССХ им. А. Н. Бакулева РАМН 2009; 162 с).Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423.Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423.Perk J, de Backer G, Gohlke G, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33: 1635–701.Perk J, de Backer G, Gohlke G, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33: 1635–701.National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and, treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and, treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002; 106: 3143–421.National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and, treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and, treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002; 106: 3143–421.Draft recommendations of experts nationwide Society of Cardiology for the diagnosis and correction of disorders of lipid metabolism for the prevention and treatment of atherosclerosis. Cardiovascular therapy and prevention 2007; 6 (6), Suppl 3. Russian (Проект рекомендаций экспертов всерос- сийского научного общества кардиологов по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. Кардиоваскулярная терапия и профилактика 2007; 6 (6), Приложение 3).Draft recommendations of experts nationwide Society of Cardiology for the diagnosis and correction of disorders of lipid metabolism for the prevention and treatment of atherosclerosis. Cardiovascular therapy and prevention 2007; 6 (6), Suppl 3. Russian (Проект рекомендаций экспертов всерос- сийского научного общества кардиологов по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. Кардиоваскулярная терапия и профилактика 2007; 6 (6), Приложение 3).EUROSPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18: 1569–82.EUROSPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18: 1569–82.Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–72.Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–72.Kotseva K, Wood D, De Backer G, et al; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121–37.Kotseva K, Wood D, De Backer G, et al; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121–37.Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults. Findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003; 107: 2185–9.Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults. Findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003; 107: 2185–9.Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low￾density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459–67.Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low￾density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459–67.Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002; 113: 625–9.Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002; 113: 625–9.EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357 (9261): 995–1001.EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357 (9261): 995–1001.Boytsov SA on behalf of Russian EURIKA investigators. Prevalence of cardiovascular risk factors and cardiovascular prevention quality in primary healthcare in Russian and European countries: EURIKA study results. Cardiovascular therapy and prevention 2012; 11 (1): 11–6. Russian (Бойцов С. А. от коллектива исследователей в Российской Федерации. Структура факторов сердечно-сосудистого риска и качество мер их профилактики в первичном звене здравоохранения в России и в Европейских странах (по результатам исследования EURIKA). Кардиоваскулярная терапия и профилактика 2012; 11 (1): 11–6).Boytsov SA on behalf of Russian EURIKA investigators. Prevalence of cardiovascular risk factors and cardiovascular prevention quality in primary healthcare in Russian and European countries: EURIKA study results. Cardiovascular therapy and prevention 2012; 11 (1): 11–6. Russian (Бойцов С. А. от коллектива исследователей в Российской Федерации. Структура факторов сердечно-сосудистого риска и качество мер их профилактики в первичном звене здравоохранения в России и в Европейских странах (по результатам исследования EURIKA). Кардиоваскулярная терапия и профилактика 2012; 11 (1): 11–6).Hermans MP, Castro Cabezas M, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin 2010; 26 (2): 445–54.Hermans MP, Castro Cabezas M, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin 2010; 26 (2): 445–54.Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375–414.Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375–414.Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227–39.Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227–39.Alberti GMM, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 1059–62.Alberti GMM, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 1059–62.European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–818.European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–818.Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005; 28: 595–9.Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005; 28: 595–9.Conroy RM, Pyorala K, Fitzgerald AP, et al, on behalf of the SCORE Project. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.Conroy RM, Pyorala K, Fitzgerald AP, et al, on behalf of the SCORE Project. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.

The authors declare that there are no conflicts of interest present.